H. Leblanc, D. Lawrence, E. Varfolomeev, K. Totpal, J. Morlan et al., Tumor-cell resistance to death receptor???induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax, Nature Medicine, vol.8, issue.3, pp.274-81, 2002.
DOI : 10.1038/nm0302-274

A. Sanlioglu, B. Karacay, I. Koksal, T. Griffith, and S. Sanlioglu, DcR2 (TRAIL-R4) siRNA and adenovirus delivery of TRAIL (Ad5hTRAIL) break down in vitro tumorigenic potential of prostate carcinoma cells, Cancer Gene Therapy, vol.16, issue.12, pp.976-84, 2007.
DOI : 10.1038/sj.cgt.7701087

A. Sanlioglu, A. Korcum, E. Pestereli, G. Erdogan, S. Karaveli et al., TRAIL Death Receptor???4 Expression Positively Correlates With the Tumor Grade in Breast Cancer Patients With Invasive Ductal Carcinoma, International Journal of Radiation Oncology*Biology*Physics, vol.69, issue.3, pp.716-739, 2007.
DOI : 10.1016/j.ijrobp.2007.03.057

R. Riccioni, L. Pasquini, G. Mariani, E. Saulle, A. Rossini et al., TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL

T. Griffith, W. Chin, G. Jackson, D. Lynch, and M. Kubin, Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells, J Immunol, vol.161, issue.6, pp.2833-2873, 1998.

D. Merino, N. Lalaoui, A. Morizot, P. Schneider, E. Solary et al., Differential Inhibition of TRAIL-Mediated DR5-DISC Formation by Decoy Receptors 1 and 2, Molecular and Cellular Biology, vol.26, issue.19
DOI : 10.1128/MCB.00520-06

URL : https://hal.archives-ouvertes.fr/inserm-00103839

M. Travert, P. Ame-thomas, C. Pangault, A. Morizot, O. Micheau et al., CD40 Ligand Protects from TRAIL-Induced Apoptosis in Follicular Lymphomas through NF-??B Activation and Up-Regulation of c-FLIP and Bcl-xL, The Journal of Immunology, vol.181, issue.2, pp.1001-1012, 2008.
DOI : 10.4049/jimmunol.181.2.1001

C. Von-haefen, B. Gillissen, P. Hemmati, J. Wendt, D. Guner et al., Multidomain Bcl-2 homolog Bax but not Bak mediates synergistic induction of apoptosis by TRAIL and 5-FU through the mitochondrial apoptosis pathway, Oncogene, vol.23, issue.50, pp.8320-8352, 2004.
DOI : 10.1038/sj.onc.1207971

L. Galligan, D. Longley, M. Mcewan, T. Wilson, K. Mclaughlin et al., Chemotherapy and TRAIL-mediated colon cancer cell death: the roles of p53, TRAIL receptors, and c-FLIP, Molecular Cancer Therapeutics, vol.4, issue.12, pp.2026-2062, 2005.
DOI : 10.1158/1535-7163.MCT-05-0262

V. Pavet, J. Beyrath, C. Pardin, A. Morizot, M. Lechner et al., Multivalent DR5 peptides activate the TRAIL death pathway and exert tumoricidal activity . Cancer research, pp.1101-1111, 2010.
URL : https://hal.archives-ouvertes.fr/hal-00451170

J. Soria, E. Smit, D. Khayat, B. Besse, X. Yang et al., Phase 1b Study of Dulanermin (recombinant human Apo2L/TRAIL) in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Patients With Advanced Non-Squamous Non???Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.28, issue.9, pp.1527-1560, 2010.
DOI : 10.1200/JCO.2009.25.4847

J. Koornstra, J. Kleibeuker, C. Van-geelen, F. Rijcken, H. Hollema et al., Expression of TRAIL (TNF-related apoptosis-inducing ligand) and its receptors in normal colonic mucosa, adenomas, and carcinomas, The Journal of Pathology, vol.20, issue.3, pp.327-362, 2003.
DOI : 10.1002/path.1364

T. Ganten, J. Sykora, R. Koschny, E. Batke, S. Aulmann et al., Prognostic significance of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in patients with breast cancer, Journal of Molecular Medicine, vol.7, issue.3, pp.995-1007, 2009.
DOI : 10.1007/s00109-009-0510-z

V. Granci, F. Bibeau, A. Kramar, F. Boissiere-michot, S. Thezenas et al., Prognostic significance of TRAIL-R1 and TRAIL-R3 expression in metastatic colorectal carcinomas, European Journal of Cancer, vol.44, issue.15, pp.2312-2320, 2008.
DOI : 10.1016/j.ejca.2008.06.042

URL : https://hal.archives-ouvertes.fr/inserm-00318854

S. Spencer, S. Gaudet, J. Albeck, J. Burke, and P. Sorger, Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis, Nature, vol.382, issue.7245, pp.428-460, 2009.
DOI : 10.1038/nature08012

M. Nagane, G. Pan, J. Weddle, V. Dixit, W. Cavenee et al., Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo, Cancer research, vol.60, issue.4, pp.847-53, 2000.

D. Nguyen, W. Yeow, M. Ziauddin, A. Baras, W. Tsai et al., The Essential Role of the Mitochondria-Dependent Death-Signaling Cascade in Chemotherapy-Induced Potentiation of Apo2L/TRAIL Cytotoxicity in Cultured Thoracic Cancer Cells, The Cancer Journal, vol.12, issue.4, pp.257-73, 2006.
DOI : 10.1097/00130404-200607000-00004

C. Ruiz-ruiz and A. Lopez-rivas, Mitochondria-dependent and -independent mechanisms in tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis are both regulated by interferon-?? in human breast tumour cells, Biochemical Journal, vol.365, issue.3, pp.825-857, 2002.
DOI : 10.1042/bj20020184

T. Wilson, K. Mclaughlin, M. Mcewan, H. Sakai, K. Rogers et al., c-FLIP: a key regulator of colorectal cancer cell death . Cancer research, pp.5754-62, 2007.

P. Mirandola, C. Ponti, G. Gobbi, I. Sponzilli, M. Vaccarezza et al., Activated human NK and CD8+ T cells express both TNF-related apoptosis-inducing ligand (TRAIL) and TRAIL receptors but are resistant to TRAIL-mediated cytotoxicity, Blood, vol.104, issue.8, pp.2418-2442, 2004.
DOI : 10.1182/blood-2004-04-1294

C. Dumitru, A. Carpinteiro, T. Trarbach, U. Hengge, and E. Gulbins, Doxorubicin enhances TRAIL-induced cell death via ceramide-enriched membrane platforms, Apoptosis, vol.314, issue.8
DOI : 10.1007/s10495-007-0081-9

L. Xu, X. Qu, Y. Zhang, X. Hu, X. Yang et al., Oxaliplatin enhances TRAIL-induced apoptosis in gastric cancer cells by CBL-regulated death receptor redistribution in lipid rafts, FEBS Letters, vol.6, issue.5, pp.943-951, 2009.
DOI : 10.1016/j.febslet.2009.02.014

D. Longley, T. Wilson, M. Mcewan, W. Allen, U. Mcdermott et al., c-FLIP inhibits chemotherapy-induced colorectal cancer cell death, Oncogene, vol.106, issue.6, pp.838-886, 2006.
DOI : 10.1016/S1074-7613(00)80214-9

O. Micheau, E. Solary, A. Hammann, and M. Dimanche-boitrel, Fas Ligand-independent, FADD-mediated Activation of the Fas Death Pathway by Anticancer Drugs, Journal of Biological Chemistry, vol.274, issue.12, pp.7987-92, 1999.
DOI : 10.1074/jbc.274.12.7987

A. Rebillard, S. Jouan-lanhouet, E. Jouan, P. Legembre, M. Pizon et al., Cisplatin-induced apoptosis involves a Fas-ROCK-ezrin-dependent actin remodelling in human colon cancer cells, European Journal of Cancer, vol.46, issue.8, 2010.
DOI : 10.1016/j.ejca.2010.01.034

URL : https://hal.archives-ouvertes.fr/hal-00659626

B. Kohler, S. Anguissola, C. Concannon, M. Rehm, D. Kogel et al., Bid Participates in Genotoxic Drug-Induced Apoptosis of HeLa Cells and Is Essential for Death Receptor Ligands' Apoptotic and Synergistic Effects, PLoS ONE, vol.26, issue.4, p.2844, 2008.
DOI : 10.1371/journal.pone.0002844.g011

G. Ullenhag, A. Mukherjee, N. Watson, A. Al-attar, J. Scholefield et al., Overexpression of FLIPL Is an Independent Marker of Poor Prognosis in Colorectal Cancer Patients, Clinical Cancer Research, vol.13, issue.17, pp.5070-5075, 2007.
DOI : 10.1158/1078-0432.CCR-06-2547

I. Koksal, A. Sanlioglu, B. Karacay, T. Griffith, and S. Sanlioglu, Tumor necrosis factor-related apoptosis inducing ligand-R4 decoy receptor expression is correlated with high Gleason scores, prostate-specific antigen recurrence, and decreased survival in patients with prostate carcinoma, Urologic Oncology: Seminars and Original Investigations, vol.26, issue.2, pp.158-65, 2008.
DOI : 10.1016/j.urolonc.2007.01.022

P. Schneider, Production of Recombinant TRAIL and TRAIL Receptor: Fc Chimeric Proteins, Methods Enzymol, vol.322, pp.325-370, 2000.
DOI : 10.1016/S0076-6879(00)22031-4

J. Morgenstern and H. Land, Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line, Nucleic Acids Research, vol.18, issue.12, pp.3587-96, 1990.
DOI : 10.1093/nar/18.12.3587

E. Cheng, M. Wei, S. Weiler, R. Flavell, T. Mak et al., BCL-2, BCL-XL Sequester BH3 Domain-Only Molecules Preventing BAX- and BAK-Mediated Mitochondrial Apoptosis, Molecular Cell, vol.8, issue.3, pp.705-716, 2001.
DOI : 10.1016/S1097-2765(01)00320-3

URL : http://doi.org/10.1016/s1097-2765(01)00320-3